Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C.

Oncotarget. 2015 Aug 7;6(22):18966-79.

2.

Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C.

Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.

PMID:
24661907
3.

Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.

Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, Filippetti F, Shahabi S, Scambia G, Ferlini C.

Biochem Pharmacol. 2012 Dec 1;84(11):1409-18. doi: 10.1016/j.bcp.2012.08.019. Epub 2012 Sep 1.

PMID:
22964220
4.

RON and cisplatin resistance in ovarian cancer cell lines.

Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G, Ferlini C.

Oncol Res. 2010;19(1):13-22.

PMID:
21141737
5.

Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.

Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G.

Cancer Res. 2009 Sep 1;69(17):6906-14. doi: 10.1158/0008-5472.CAN-09-0540. Epub 2009 Aug 11.

6.

Molecular mechanisms of patupilone resistance.

Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C.

Cancer Res. 2008 Dec 15;68(24):10197-204. doi: 10.1158/0008-5472.CAN-08-2091.

7.

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.

8.

Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.

Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, Ferrandina G, Costanzo A, Tuosto L.

Mol Cancer Ther. 2008 Jun;7(6):1410-9. doi: 10.1158/1535-7163.MCT-08-0299.

9.

Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G.

Curr Cancer Drug Targets. 2007 Dec;7(8):704-12. Review.

PMID:
18220531
10.

From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G, Ferlini C.

Mol Cancer Ther. 2008 Jan;7(1):233-41. doi: 10.1158/1535-7163.MCT-07-0390. Epub 2008 Jan 9.

11.

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.

Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C.

Gene. 2008 Feb 15;409(1-2):100-8. doi: 10.1016/j.gene.2007.11.015. Epub 2007 Dec 3.

PMID:
18178340
12.

Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.

Gallo D, Mantuano E, Fabrizi M, Ferlini C, Mozzetti S, De Stefano I, Scambia G.

Endocr Relat Cancer. 2007 Jun;14(2):317-24.

PMID:
17639047
13.

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, Mozzetti S, Scambia G, Ferlini C.

Clin Cancer Res. 2006 May 1;12(9):2774-9.

14.

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G.

Cancer Res. 2005 Mar 15;65(6):2397-405.

15.

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G.

Clin Cancer Res. 2005 Jan 1;11(1):298-305.

16.

Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, Scambia G.

Biochem Pharmacol. 2005 Jan 1;69(1):113-21.

PMID:
15588720
17.

The unsolved enigma of CDH1 down-regulation in hereditary diffuse gastric cancer.

Concolino P, Papa V, Mozzetti S, Ferlini C, Pacelli F, Martinelli E, Ricci R, Filippetti F, Scambia G, Doglietto GB.

J Surg Res. 2004 Sep;121(1):50-5.

PMID:
15313375
18.

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G.

Mol Pharmacol. 2003 Jul;64(1):51-8.

19.

Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample.

Marone M, Mozzetti S, De Ritis D, Pierelli L, Scambia G.

Biol Proced Online. 2001 Nov 16;3:19-25.

20.

Cell cycle regulation in human hematopoietic stem cells: from isolation to activation.

Marone M, De Ritis D, Bonanno G, Mozzetti S, Rutella S, Scambia G, Pierelli L.

Leuk Lymphoma. 2002 Mar;43(3):493-501. Review.

PMID:
12002751
21.

Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells.

Ferrandina G, Filippini P, Ferlini C, Maggiano N, Stoler AB, Fruscella E, Mozzetti S, Mancuso S, Freedman RS, Scambia G, Ranelletti FO.

Oncol Res. 2000;12(9-10):429-40.

PMID:
11697821
22.

Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues.

Mozzetti S, Ferrandina G, Marone M, D'Ingiullo F, Fruscella E, De Pasqua A, Mancuso S, Scambia G.

Cancer Detect Prev. 2000;24(6):536-41.

PMID:
11198267
23.

High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-xL-expressing CD34+-proliferating haematopoietic progenitors.

Marone M, Pierelli L, Mozzetti S, Masciullo V, Bonanno G, Morosetti R, Rutella S, Battaglia A, Rumi C, Mancuso S, Leone G, Giordano A, Scambia G.

Br J Haematol. 2000 Sep;110(3):654-62.

PMID:
10997978
24.

Bcl-2, bax, bcl-x(L) and bcl-x(S) expression in neoplastic and normal cervical tissue.

Ferrandina G, Mozzetti S, Marone M, Fagotti A, Macchia G, Mancuso S, Scambia G.

Cancer Lett. 2000 Jul 3;155(1):19-27.

PMID:
10814875
25.

Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential.

Pierelli L, Marone M, Bonanno G, Mozzetti S, Rutella S, Morosetti R, Rumi C, Mancuso S, Leone G, Scambia G.

Blood. 2000 May 15;95(10):3001-9.

26.

CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/- precursors.

Pierelli L, Scambia G, Bonanno G, Rutella S, Puggioni P, Battaglia A, Mozzetti S, Marone M, Menichella G, Rumi C, Mancuso S, Leone G.

Br J Haematol. 2000 Mar;108(3):610-20.

PMID:
10759721
27.

Bcl-2, Bax, Bcl-x(L) and Bcl-x(S) expression in neoplastic and normal endometrium.

Marone M, Ferrandina G, Macchia G, Mozzetti S, de Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G.

Oncology. 2000 Feb;58(2):161-8.

PMID:
10705244
28.

Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors.

Pierelli L, Scambia G, Fattorossi A, Bonanno G, Battaglia A, Rumi C, Marone M, Mozzetti S, Rutella S, Menichella G, Romeo V, Mancuso S, Leone G.

Br J Haematol. 1998 Sep;102(5):1139-50.

PMID:
9753035
29.

bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues.

Marone M, Scambia G, Mozzetti S, Ferrandina G, Iacovella S, De Pasqua A, Benedetti-Panici P, Mancuso S.

Clin Cancer Res. 1998 Feb;4(2):517-24.

30.

Concurrent HPV infection in oral and genital mucosa.

Badaracco G, Venuti A, Di Lonardo A, Scambia G, Mozzetti S, Benedetti Panici P, Mancuso S, Marcante ML.

J Oral Pathol Med. 1998 Mar;27(3):130-4.

PMID:
9563805

Supplemental Content

Loading ...
Support Center